The board of directors of Peijia Medical Limited announced that by September 17, 2020, the Company has completed the patient enrollment process for the clinical trial of TaurusElite®, the second-generation transcatheter aortic valve replacement ("TAVR") product independently developed by the Company. Compared to TaurusOne ®, the Company's first-generation TAVR device and Core Product (within the meaning ascribed thereto in Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited), TaurusElite® contains a delivery catheter system (DCS) with retrieving function, allowing physicians to retrieve the prosthetic aortic valve (PAV) if the initial release position is not ideal, thereby further increasing the safety of the product. The Company initiated a multi-center clinical trial for TaurusElite® in December 2019, and on September 8, 2020, TaurusElite ® was recognized as an "Innovative Medical Device" by the National Medical Products Administration of the PRC (NMPA), and is therefore eligible for an expedited approval process.